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Behavioral, biological, and social sequelae that lead to drug addiction differ between
men and women. Our efforts to understand addiction on a mechanistic level must
include studies in both males and females. Stress, anxiety, and depression are tightly
linked to addiction, and whether they precede or result from compulsive drug use
depends on many factors, including biological sex. The neuropeptide dynorphin (DYN),
an endogenous ligand at kappa opioid receptors (KORs), is necessary for stress-induced
aversive states and is upregulated in the brain after chronic exposure to drugs of abuse.
KOR agonists produce signs of anxiety, fear, and depression in laboratory animals and
humans, findings that have led to the hypothesis that drug withdrawal-induced DYN
release is instrumental in negative reinforcement processes that drive addiction. However,
these studies were almost exclusively conducted in males. Only recently is evidence
available that there are sex differences in the effects of KOR activation on affective state.
This review focuses on sex differences in DYN and KOR systems and how these might
contribute to sex differences in addictive behavior. Much of what is known about how
biological sex influences KOR systems is from research on pain systems. The basic
molecular and genetic mechanisms that have been discovered to underlie sex differences
in KOR function in pain systems may apply to sex differences in KOR function in reward
systems. Our goals are to discuss the current state of knowledge on how biological sex
contributes to KOR function in the context of pain, mood, and addiction and to explore
potential mechanisms for sex differences in KOR function. We will highlight evidence
that the function of DYN-KOR systems is influenced in a sex-dependent manner by:
polymorphisms in the prodynorphin (pDYN) gene, genetic linkagewith themelanocortin-1
receptor (MC1R), heterodimerization of KORs and mu opioid receptors (MORs), and
gonadal hormones. Finally, we identify several gaps in our understanding of “if” and “how”
DYN and KORs modulate addictive behavior in a sex-dependent manner. Future work
may address these gaps by building on the mechanistic studies outlined in this review.
Ultimately this will enable the development of novel and effective addiction treatments
tailored to either males or females.
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There is increasing evidence in humans and laboratory animals for biologically-based sex
differences in every phase of drug addiction: acute reinforcing effects, transition from occasional
to compulsive use, withdrawal-associated negative affective states, craving, and relapse (Griffin
et al., 1989; McKay et al., 1996; Lynch and Taylor, 2004; Lynch, 2006; Fox and Sinha, 2009;
Greenfield et al., 2010). In general, as an individual moves from impulsive to compulsive
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drug use, it is thought that a shift occurs such that negative
reinforcement dominates over positive reinforcement as the
driving force for motivated behavior (Koob, 2008). Although
the qualities and magnitude of drug withdrawal syndromes
vary among different class of drugs, withdrawal exacerbates
reward deficits that contribute to negative reinforcement and
contributes to drug craving and relapse (Kenny, 2007; Koob
and Le Moal, 2008). Furthermore, repeated drug exposure
produces long-lasting neural adaptations that sensitize the
organism to drugs and drug-associated cues. Thus, in humans,
motivational focus narrows to drug seeking at the expense of
natural reward seeking. Consistent with negative reinforcement
mechanisms of addiction, one consistent finding in human
studies is that drug-dependent women express greater negative
emotional states such as stress and depression (Griffin et al.,
1989), and these are more likely to trigger craving and relapse
in women than men (McKay et al., 1996; Fox and Sinha,
2009). The predominance of comorbid mood disorders in female
drug addicts likely arises from preexisting psychopathologies.
In the population as a whole, women are twice as likely as
men to suffer from anxiety and depression (Kessler, 2003).
Although women are more likely to seek treatment, they
experience longer episodes of depression and lower rates of
recovery (Weissman and Olfson, 1995). Thus, sex differences
in stress and reward pathways may explain why women are
more vulnerable than men to the negative consequences of drug
dependence (Becker et al., 2012). Paradoxically, the prevalence
of drug dependence is generally reported to be higher in adult
men compared to women (Carroll et al., 2004). Interestingly,
more recent epidemiological studies indicate a narrowing
in this gender gap (Substance Abuse and Mental Health
Services Administration, 2014)—particularly in adolescents.
This may reflect changing sociocultural patterns, rather than
biology.
Chronic exposure to drugs of abuse elicits neuroadaptations
in stress and reward pathways, including enhanced synthesis
and release of dynorphin (DYN)—an endogenous ligand at
kappa opioid receptors (KORs; Chavkin et al., 1982). Several
studies have shown that psychostimulant-induced increases
in DYN signaling are coincident with the emergence of
depressive-like effects including anhedonia and anxiety (Hurd
and Herkenham, 1993; Cole et al., 1995; Shippenberg et al.,
2007). However, relatively little is known about the role of
DYN and KORs in motivated behavior or drug withdrawal-
induced negative affective states in females. Recent work from
our lab shows that female rats are less sensitive than males
to the depressive-like effects of a KOR agonist (Russell et al.,
2014) raising the possibility that the contribution of KORs
to negative reinforcement processes differs between the sexes.
The purpose of this review is to discuss the current state
of knowledge on the regulation and role of DYN and KORs
within neural circuits important for emotional processing, with
particular emphasis on putative mechanistic underpinnings
of these sex differences. Given the nascent state of this
field, we will also discuss more established data on sex
differences in the role of KORs in nociception with the goal
of identifying overlapping mechanisms as well as gaps in our
knowledge.
DYNORPHIN AND KAPPA OPIOID
RECEPTORS (KORs)
Dynorphins are a class of opioid peptides that arise from the
precursor protein prodynorphin (pDYN) and act as endogenous
ligands at the KOR (Chavkin and Goldstein, 1981). DYN and
KORs are found throughout the central and peripheral nervous
system (Mansour et al., 1988, 1995; Le Merrer et al., 2009), where
they modulate a diverse set of physiological outputs including
nociception, hypothermia, and water diuresis (Vonvoigtlander
et al., 1983), as well as motivated behavior and affective states
(Bruchas et al., 2010; Knoll and Carlezon, 2010). Protease
cleavage of pDYN during processing releases multiple active
peptides selective for the KOR including DYN A1−8 & 1−17,
DYN B, and α/β-neoendorphins (Chavkin, 2013). The human
pDYN gene contains four exons: exons 1 and 2 encode the 5′
untranslated region (UTR), exon 3 encodes a signal peptide,
and exon 4 encodes the DYN peptides (Horikawa et al., 1983).
The pDYN gene contains a non-canonical activating protein 1
(AP-1)-Iike site in its promoter region, which is a target for
Fos/Jun trans-activation. In addition, the pDYN promoter has
been shown to contain three cAMP response elements (CRE)
elements, which are targets for CRE binding protein (CREB)—
mediated transcriptional activation (Douglass et al., 1989, 1994;
Cole et al., 1995).
Dynorphins are contained in large dense core vesicles and
primarily released in a calcium-dependent manner (Chavkin
et al., 1983). They can be released from nerve terminals to
cause presynaptic autoinhibition or from dendrites to cause
retrograde inhibition of afferents (for review, see Simmons
and Chavkin, 1996). Activation of KORs leads to a variety of
effects on intracellular signaling pathways, including decreased
cAMP production, increased K+ and decreased Ca2+ channel
conductance, and activation of extracellular signal-regulated
kinase (ERK) pathways (Grudt and Williams, 1995; Law et al.,
2000; Bruchas et al., 2008; Potter et al., 2011). After sustained
KOR activation, receptor desensitization can occur in which
G-protein coupled receptor kinase 3 (GRK3) phosphorylates
the KOR at serine 369 (KOR-P) (Liu-Chen, 2004). This
initiates arrestin-dependent receptor internalization and creates
a receptor-protein complex that recruits additional second
messenger signaling systems (Bruchas and Chavkin, 2010).
There is evidence in adults that gonadal hormones can
regulate the expression and release of dynorphins in spinal cord,
hypothalamic nuclei and in hippocampus (Gintzler et al., 2008;
Gottsch et al., 2009; Torres-Reveron et al., 2009). These effects
have not yet been tested for a connection to drug reward and
addictive behavior. To date, the little information available on
sex differences in KOR systems comes primarily from studies on
KOR-mediated antinociception (Rasakham and Liu-Chen, 2011).
INFLUENCE OF SEX ON BRAIN AND
BEHAVIOR
Sex differences in behavior can be classified into three main types
(McCarthy and Arnold, 2011). First, behavioral endpoints can
exist in either “male” or “female” forms or be present in one sex
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and absent in the other. Since both men and women can become
addicted to drugs, there is not an absolute sexual dimorphism
in addiction per se. However, it is possible that drugs of abuse
produce a specific behavioral or neurochemical outcome in only
one sex. Second, behavioral endpoints can exist on a spectrum in
which the average behavior is different in males and females (e.g.,
pain thresholds and analgesic efficacy of opioid painkillers). This
is the most commonly observed type of sex difference in drug
addiction research. A challenge for neuroscientists is ascertaining
whether such differences are socially or biologically based. Third,
behavioral endpoints can be the same in males and females, but
the underlying neural mechanisms that produce the behavior
can be different (e.g., certain stress responses). This type of sex
difference often goes undetected or unreported, since there are
no overt behavioral differences between males and females. But
sex differences in the mechanisms that lead to addictive behavior
could profoundly influence the way in which addiction is
treated.
The X and Y sex chromosomes are the origin of all biological
sex differences (McCarthy and Arnold, 2011). Expression of
the Y-linked gene, Sry, leads to testes development in males,
which subsequently secrete testosterone (Goodfellow and Lovell-
Badge, 1993; Becker et al., 2005). In the absence of Sry, ovaries
develop, which secrete estrogen and progesterone. The timing
and mechanisms by which the sex chromosomes influence sexual
dimorphism vary in three primary ways. First, there are direct
effects of genes expressed on X and Y chromosomes on brain and
somatic tissues. This can be through unique gene expression or
sex-dependent expression levels of the same genes. For example,
Sry is expressed in midbrain dopamine-containing cells and
has direct male-specific effects (Dewing et al., 2006). The gene
Xist is expressed from one of the two X chromosomes in non-
germline cells in females and is responsible for inactivation of
that chromosome, thus insuring that gene expression between
males and females is fairly consistent. However, some genes
escape X inactivation in a tissue-specific manner. For example,
pDYN gene expression is higher in the striatum of XX mice,
independent of gonadal hormones, suggesting that inactivation
is incomplete, at least in this brain region (Chen et al., 2009). The
second way that sex chromosomes influence sexual dimorphism
is through organizational effects of gonadal hormones during
fetal and neonatal periods. The effects of circulating gonadal
hormones on brain development in humans are greatest during
weeks 8 through 24 of gestation (McCarthy, 2010). During
this critical period, neural structures are still being established
in the fetus. At this time, male fetuses secrete over 2.5 times
more testosterone than females (Auyeung et al., 2013). In males,
circulating testosterone is aromatized to estradiol in the central
nervous system. There it masculinizes and defeminizes the brain,
modulating synapses and shaping the formation of brain regions
(McCarthy and Arnold, 2011). For example, organizational
processes sexualize brain structures such as the preoptic area and
the suprachiasmatic nucleus of the hypothalamus, the basolateral
amygdala (BLA), the bed nucleus of the stria terminalis (BNST),
and the corpus callosum (Collaer and Hines, 1995). Of particular
importance to addiction and mood disorders are the amygdala
and the BNST (Bruchas et al., 2010; Knoll and Carlezon,
2010). Third, there are activational effects of circulating gonadal
hormones during and after puberty (McCarthy et al., 2012)
Fluctuations in hormone secretion may affect behaviors on
a short-term scale, but are quickly mitigated after steroid
concentrations return to baseline(McCarthy et al., 2012).
The steroid hormones testosterone, estrogen, and
progesterone activate androgen (AR), estrogen α and β (ERα
and ERβ), and progesterone (PR) receptors, respectively. These
act primarily as nuclear transcription factor receptors capable
of directly interacting with DNA at specific response elements
and modulating gene transcription (Beato, 1989). It is also clear,
from more recent research, that steroid hormones act rapidly
on membrane bound receptors to activate signal transduction
pathways with broad effects on cellular physiology (Balthazart
and Ball, 2006). Indeed, a new membrane-bound G protein-
coupled estrogen receptor (GPER-1/GPR30) has been identified
(Revankar et al., 2005) and implicated in the non-genomic
effects of estrogen (Elkabes and Nicot, 2014). Both males and
females can produce testosterone and estrogen, although the
divergent effects of these steroid hormones are mediated by sex
differences in their levels, distribution and metabolism, as well as
the levels and distribution of their cognate receptors (McCarthy
and Arnold, 2011). Although there are many hormone-sensitive
areas of the brain, of particular importance to drug addiction is
the presence of steroid hormone receptors within neural circuits
associated with mood regulation and stress sensitivity, such as
the mesocorticolimbic system, the extended amygdala, and the
hypothalamic pituitary adrenal (HPA) axis (see Figure 1). As
such, it is likely that both organizational and activational effects
of gonadal hormones within these neural circuits contribute to
sex differences in motivated behavior and affective states.
ROLE OF KOR SYSTEMS IN PAIN
Human
Sex differences have been reported in the perception of pain
(Gear et al., 1996; Fillingim, 2000; Sibille et al., 2011) and in
the efficacy of opioid analgesics to ameliorate pain (Fillingim
et al., 2004; Zacny and Beckman, 2004; Bodnar and Kest, 2010;
Rasakham and Liu-Chen, 2011). In general, women tend to
demonstrate lower pain thresholds, less pain tolerance and higher
evoked pain intensity (Gear et al., 1996; Riley et al., 1998; Sibille
et al., 2011) as well as report higher pain ratings (Zacny and
Beckman, 2004). However, there is significant variability between
and within studies, the effect sizes are often very small, and sex
differences only exist for some types of pain measures (Berkley,
1997; Wiesenfeld-Hallin, 2005).
Similar to MOR agonists such as endorphins and morphine,
DYN and exogenous KOR agonists have antinociceptive
properties (Han and Xie, 1982, 1984) but with a much lower
abuse potential (Fraser and Rosenberg, 1964). Just as sex
differences in the perception of pain are complex, the analgesic
effects of opioids in men and women depend on the specific
type of pain and the opioid analgesic. Mixed KOR/MOR partial
agonists including pentazocine, nalbuphine, and butorphanol
have been shown to produce greater analgesia in women
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FIGURE 1 | Top: Distribution of kappa opioid (7-transmembrane receptor), estrogen, and androgen receptors within neural circuits involved in pain. Brain regions
shaded in blue are primarily associated with sensory dimensions of pain whereas those shaded in red are primarily associated with affective dimensions of pain. There
is crosstalk between the various brain regions (see Cahill et al., 2014 for review). Bottom: Distribution of kappa opioid, estrogen, and androgen receptors within neural
circuits involved in affective state and motivated behavior. Brain regions shaded in blue are primarily associated with the mesocorticolimbic dopamine system and
reward processing. Brain regions shaded in red are primarily associated with stress and anxiety (negative affective states). Expression of KORs, ERs, and ARs is
qualitatively similar between males and females. The final impact of KOR activation on neuronal function and behavior depends on the cellular localization of the
receptor (e.g., pre- or post-synaptic) and the projection target of the KOR-expressing neuron. Currently this level of detail is relatively unexplored in male vs. female
brain. Receptor expression in this figure is based on evidence of overlapping mRNA expression and receptor binding: indicated brain regions are thought to synthesize
and express the indicated receptors (Morris and Herz, 1987; Mansour et al., 1988, 1995; Besse et al., 1990; Simerly et al., 1990; Arvidsson et al., 1995; Lumbroso
et al., 1996; Shughrue et al., 1997; Laflamme et al., 1998; Slowe et al., 1999; Papka et al., 2001; Hamson et al., 2004; Harris et al., 2004; Vanderhorst et al., 2005;
Loyd and Murphy, 2008; Le Merrer et al., 2009; Feng et al., 2010; Rasakham and Liu-Chen, 2011). ACC, anterior cingulate cortex; AMG, amygdala; AR, androgen
receptor; BNST, bed nucleus of the stria terminalis; DH, dorsal horn of spinal cord; DRG, dorsal root ganglia; EP, endopiriform cortex; ER, estrogen receptor; HIP,
hippocampus; LC, locus coeruleus; NAc, nucleus accumbens; OFC, orbitofrontal cortex; PAG, periaqueductal gray; PB, parabrachial nucleus; PFC, prefrontal cortex;
PVN, paraventricular nucleus of the hypothalamus; RVM, rostral ventral medulla; VH, ventral horn of the spinal cord; VTA, ventral tegmental area.
compared to men in post-operative dental surgery (Gear et al.,
1996, 1999). Similarly, the analgesic effect of pentazocine has
been shown to be more robust in women for ischemic and
thermal pain (Mogil et al., 2003). In contrast, Fillingim et al.
(2004) reported no sex differences in the analgesic effects of
pentazocine in models of heat, ischemic and pressure pain.
There are also numerous examples in which opioid analgesics
have greater effects in men. The partial MOR/KOR agonist
butorphanol produces higher analgesic ratings in men in the
cold-water stimulus pain assay (Zacny and Beckman, 2004),
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although other studies suggest no sex differences in the analgesic
effects of either the MOR agonist morphine or butorphanol
(Sibille et al., 2011). Importantly, clearance of butorphanol has
been shown to be lower in women compared to men, raising
the possibility that pharmacokinetic differences between men
and women are a factor and should be considered in dose
determinations (Shyu et al., 1994). Taken together, it is almost
impossible to draw sweeping conclusions about how sex impacts
pain and analgesia. Rather, the findings to date highlight the
importance of studying each facet of analgesia in both men and
women and suggest that genetic variability plays a major role.
Animals
According to a recent analysis, approximately 80% of the animals
studies published in the journal “Pain” in the last decade have
been done in males and only 4% of those studies were designed
to test pain perception in both sexes (Bodnar and Kest, 2010).
Animal studies examining sex differences in pain or analgesic
sensitivity have revealed that the presence and direction of sex
differences are dependent on the strain chosen for study (Mogil
et al., 2000). The interactions between sex and genetics on pain
response are still relatively unexplored, but identification of
relevant genes should facilitate development of more effective
analgesics for both men and women.
Interestingly, animal studies tend to demonstrate more robust
analgesic effects of KOR ligands in males compared to females,
whereas the opposite is generally true in human studies (see
Rasakham and Liu-Chen, 2011). For example, the selective KOR
agonist U50,488 has more robust analgesic effects in male rats
andmice compared to females in the tail flick assay (Kavaliers and
Innes, 1987; Barrett et al., 2002; Mogil et al., 2003; Sternberg et al.,
2004a; Stoffel et al., 2005), although this does not hold for every
strain (Rasakham and Liu-Chen, 2011). Reproductive hormones
such as testosterone and estradiol do not seem to significantly
modulate sensitivity to the analgesic effects of opioids under
many—but not all—conditions (Stoffel et al., 2005). The sex
differences in the antinociceptive effects of KOR agonists have
been suggested to be primarily spinal rather than supraspinal
dependent (Craft and Bernal, 2001).
Neuroanatomy of KORs Related to Pain
DYN and KORs in the peripheral and central nervous system
play major roles in the sensory and affective components of pain
(Cahill et al., 2014). As such, the neural circuits sub serving
pain and affect are at least partially overlapping (see Figure 1).
Chronic pain stimuli lead to sustained DYN release in the spinal
cord, which is thought to be a compensatory analgesic response
(Iadarola et al., 1988; Cahill et al., 2014). Thus, it is thought
that analgesic effects of KOR activation are due in part to
DYN and KOR localization in the spinal cord and brain stem,
where they act to inhibit pain pathways (Millan et al., 1989;
Watkins et al., 1992; Simonin et al., 1995; Yaksh, 1997; Cahill
et al., 2014). In the spinal cord, KORs are localized pre- and
post-synaptically (Ji et al., 1995): a proportion are expressed
in the superficial dorsal horn of the spinal cord (Gouardères
et al., 1986; Maekawa et al., 1994; Mansour et al., 1994b, 1996;
Arvidsson et al., 1995) and a proportion (∼50%) on sensory
afferents from the dorsal root ganglion (Besse et al., 1990;
Maekawa et al., 1994; Mansour et al., 1994b, 1996; Arvidsson
et al., 1995). KORs are also co-expressed with other opioid
receptors (mu and delta) on primary sensory neurons. In rat and
rabbit, the highest levels of DYN immunoreactivity have been
observed in the dorsal part of the spinal cord, and the lowest
levels in the dorsal root ganglia (Botticelli et al., 1981). KOR
agonists have been shown to modulate excitatory transmission
in substantia gelatinosa neurons of the rat spinal cord via
inhibition of AMPA-mediated neurotransmission (Randic et al.,
1995).
In addition to spinal actions of DYN (Han and Xie,
1982), there is evidence supporting analgesic KOR effects at
supraspinal sites (Cahill et al., 2014) including parietal cortex
and amygdala (Abraham et al., 2000; Narita et al., 2006). The
rostral ventromedial medulla (RVM) has also been shown to be a
crucial site for the supraspinal antinociceptive actions of opioids.
In particular, the nucleus raphe magnus forms a component
of a descending inhibitory network that modulates nociceptive
neurotransmission at the level of the spinal cord dorsal horn
(Marinelli et al., 2002). This nucleus projects to the spinal cord
and approximately 20% of the neurons respond to KOR ligands
(Marinelli et al., 2002). Pain transmission pathways from the
periphery to the CNS involve projections from the medulla to the
midbrain and more anterior structures (Al-Hasani and Bruchas,
2011), which overlap with structures involved in KOR effects on
affective state (see Figure 1).
ROLE OF KOR SYSTEMS IN AFFECTIVE
STATE
Human
Based on the hypothesis that KOR agonists could be utilized
as non-addictive analgesics, a major effort was initiated to
develop and test KOR-selective ligands in pain models. However,
patients (only males were included in these early studies)
reported aversive and depressive signs (including dysphoria) after
treatment with non-selective KOR agonists such as cyclazocine,
spiradoline, and the more selective KOR agonist MR2033
(Pfeiffer et al., 1986; Chappell et al., 1993). Interestingly,
pentazocine, a relatively specific KOR partial agonist/MOR
antagonist (Zhu et al., 1997) is still used for obstetrical pain,
perhaps because females are less sensitive to the aversive
effects of KOR activation (Russell et al., 2014). Indeed, a case
report describes antidepressant effects of the naturally occurring
hallucinogen Salvia divinorum, a rare member of the mint
family in which the active ingredient is the highly selective and
potent KOR agonist, salvinorin A, in a woman with intractable
depression (Hanes, 2001). In contrast to this, a retrospective
survey of recreational Salvia users reported similar levels of
drug-induced anxiety in men and women (Gonzalez et al.,
2006). Given the negative effects of KOR agonists on mood,
drug development efforts for KOR ligands as analgesics were
largely halted. However, the information gleaned from these
studies has been instrumental in our understanding of the role
of DYN/KORs in affective state and has led to novel hypotheses
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about the clinical utility of KOR-selective compounds (Carlezon
et al., 2009).
One such hypothesis is that KOR-mediated reductions in
hyperdopaminergia may reduce symptoms of mania in people
with bipolar disorder. This was tested using pentazocine in a
small open-label study in 10 patients (7 male and 3 female)
with mania. Pentazocine reduced manic symptoms transiently
but substantially and significantly in each subject without causing
notable sedation or affecting psychotic symptoms (Cohen and
Murphy, 2008).
A second hypothesis that has gained traction is that
KOR antagonists may reduce depressive-like symptoms that
characterize numerous psychiatric disorders including major
depressive disorder (MDD), post-traumatic stress disorder
(PTSD), and drug addiction. In support of this, buprenorphine,
a partial MOR agonist/ KOR antagonist, has been shown to
have antidepressant efficacy in MDD in observational studies
(Emrich et al., 1982; Walsh et al., 1994, 1995; Bodkin et al.,
1995; Cowan, 2003; Nyhuis et al., 2008; Karp et al., 2014) and
to reduce depressive symptoms in heroin addicted patients who
were depressed at intake (Kosten et al., 1990). Amazingly, these
studies were conducted only in males or, when females were
included, no information is provided on the contribution of
gender to the results. More recently, attempts have been made
to isolate the KOR antagonist properties of buprenorphine by
co-administering MOR antagonists. Rothman and colleagues
hypothesized that a KOR antagonist would alleviate dysphoria
observed in the protracted opiate withdrawal syndrome and
as such reduce rates of relapse in abstinent opioid-dependent
patients. A combination of buprenorphine and the MOR
antagonist naltrexone has been shown to produce a substantial
reduction in cocaine and opiate use (Rothman et al., 2000; Gerra
et al., 2006). Perhaps themost compelling clinical data supporting
antidepressant effects of KOR antagonists come from a recent
study in which a combination of buprenorphine and the potent
MOR antagonist samidorphan administered to subjects with
treatment resistant MDD resulted in significant and substantial
antidepressant activity without addictive potential (Ehrich et al.,
2015).
At this point there is little conclusive evidence regarding
sex differences in the direct role of DYN and KOR systems
in drug addiction in humans. However, there is increasing
evidence for sex differences in the role of KORs in mediating
stress responses and affective states in preclinical animal
models, which may help us understand, on a mechanistic
level, why addiction is experienced differently in men and
women.
Animals
In males, activation of KORs produces depressive-like and
anxiogenic behaviors (Bals-Kubik et al., 1989; Todtenkopf et al.,
2004; Carlezon et al., 2006; Tomasiewicz et al., 2008; Ebner et al.,
2010; Knoll et al., 2011; Muschamp et al., 2011), encodes the
dysphoric component of stress (Land et al., 2008; Bruchas et al.,
2010), and can promote drug-seeking behavior (Negus, 2004;
McLaughlin et al., 2006; Redila and Chavkin, 2008; Schindler
et al., 2010). Likewise, KOR blockade has antidepressant and
anxiolytic effects (Pliakas et al., 2001; Newton et al., 2002;
Mague et al., 2003; Knoll et al., 2007), attenuates aversive states
associated with cocaine withdrawal (Chartoff et al., 2012), and
attenuates drug-seeking behavior (Beardsley et al., 2005; Carey
et al., 2007; Walker and Koob, 2007; Redila and Chavkin, 2008;
Land et al., 2009; Wee et al., 2009; Bruchas et al., 2010). These
findings are consistent with observations that KOR agonists
produce dysphoric and depressive-like states in men (Pfeiffer
et al., 1986).
We recently demonstrated that female rats are less sensitive
than males to the depressive-like effects of the KOR agonist
U50,488 (Russell et al., 2014) using intracranial self-stimulation
(ICSS), an operant behavior that is sensitive to increases and
decreases in reward function (Carlezon and Chartoff, 2007).
This effect is independent of circulating gonadal hormones,
as gonadectomy did not alter responses to U50,488 (Russell
et al., 2014). Cellular mapping showed U50,488-induced c-
Fos activation to be greater in corticotropin releasing factor
(CRF)-containing neurons of the paraventricular nucleus of the
hypothalamus (PVN) and in non-CRF-containing neurons of
the BNST oval nucleus in females compared to males (Russell
et al., 2014). In an earlier study, it was shown that female
rats take significantly longer than males to discriminate the
KOR agonist U69,593 from vehicle using an FR-10 schedule of
food reinforcement (Craft et al., 1998). The ED50 for U69,593
discrimination was significantly higher in females, and the peak
and offset for U69,593 occurred earlier in females compare to
the males (Craft et al., 1998). In contrast, Robles et al. (2014)
demonstrated in the California mouse that females formed
conditioned place aversions to a low, but place preferences to
a high, dose of U50,488. However, males were insensitive to
the low and formed conditioned place aversions to the high
dose of U50,488. Together these findings highlight how species
and behavioral paradigm play a major role in the function of
KORs.
In males, co-administration of KOR agonists with cocaine
has been shown to prevent the development of locomotor
sensitization to cocaine as well as cocaine-induced conditioned
place preferences (Heidbreder et al., 1995; Shippenberg and Rea,
1997). However, there is emerging evidence that prolonged or
prior exposure to KOR agonists can potentiate the effects of
cocaine. For example, exposure to KOR agonists can increase
the locomotor stimulant effects of psychostimulants as well as
stimulated dopamine release in striatal regions, depending on
the timing and context of KOR agonist exposure (Heidbreder
et al., 1998; Fuentealba et al., 2006, 2007; Chartoff et al., 2008).
Continuous treatment of rhesus monkeys with the KOR agonist
U50,488 increases cocaine choice (Negus, 2004), suggesting a
KOR-mediated increase in the relative reinforcing effects of
cocaine. Pretreatment with KOR agonists can potentiate cocaine-
induced place preferences (McLaughlin et al., 2006) and brain
stimulation reward (Chartoff et al., 2015), and activation of KORs
can reinstate cocaine seeking (Redila and Chavkin, 2008). One
explanation for KOR-mediated potentiation of cocaine reward
that has been proposed (McLaughlin et al., 2006) is that activation
of KORs prior to administration of cocaine produces a dysphoric
state that enhances the rewarding properties of cocaine. This
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raises the possibility that, in females, KOR activation would fail
to potentiate reward-related effects of drugs of abuse. This has
yet to be directly tested.
Consistent with idea that KOR activation can enhance
psychostimulant effects in males but not females, it has been
reported that pretreatment with the non-selective KOR agonist
spiradoline potentiates acute cocaine-induced locomotor activity
in male, but not female, mice (Sershen et al., 1998). Further
in vitro analyses indicated that the ability of spiradoline to
inhibit NMDA-evoked dopamine release in striatal slices was
lower in female compared to male tissue (Sershen et al., 1998).
This is consistent with the general concept that the net change
(delta) in dopamine signaling determines behavioral responses
to cocaine (Ehrich et al., 2014; Chartoff et al., 2015). In guinea
pigs, which have KOR expression levels and distributions quite
similar to humans, the effects of the KOR agonist U50,488
on basal measures of body posture and analgesia were shown
to be consistently lower in females compared to males (Wang
et al., 2011). KOR effects on basal locomotor activity did not
differ betweenmales and females, whereas acute cocaine-induced
locomotor activity was substantially higher in females compared
to males. In the same study, U50,488 produced greater decreases
in cocaine-induced locomotor activity in female guinea pigs
compared to males—bringing activity down to levels observed in
males treated with cocaine alone (Wang et al., 2011). Although
it’s difficult to reconcile the findings described above, with
one study reporting KOR-mediated increases in cocaine effects
(Sershen et al., 1998) and the other study reporting KOR-
mediated decreases (Wang et al., 2011), the studies highlight
the importance of species, drug, and experimental design in
modulating KOR effects. Furthermore, these studies touch
upon the important interactions of KORs with the mesolimbic
dopamine system and are broadly consistent with studies
showing greater evoked dopamine release in female compared
to male nucleus accumbens (Walker et al., 2000). It is possible
that enhanced dopamine function can protect females from the
inhibitory effects of KOR activation.
Neuroanatomy of KORs Related to
Affective State
In mammals, KORs are expressed throughout brain regions
involved in affect, cognition, and motivated behavior, including
the ventral tegmental area (VTA), nucleus accumbens (NAc),
prefrontal cortex (PfC), hippocampus, dorsal striatum, amygdala,
BNST, locus coeruleus, substantia nigra, dorsal raphe nucleus,
pedunculpontine nucleus, and hypothalamus (Mansour et al.,
1994a,b, 1995, 1996; Peckys and Landwehrmeyer, 1999; Svingos
et al., 1999; Margolis et al., 2003; Le Merrer et al., 2009). The
effect of KOR activation on neural transmission depends on
the phenotype (e.g., excitatory or inhibitory) of the neuron
expressing KORs, its projection target, and whether the receptor
is expressed pre- or post-synaptically. These criteria have been
elegantly described for KOR-mediated modulation of VTA
dopamine neurotransmission. Broadly, KOR activation inhibits
dopamine release (Margolis et al., 2003, 2005, 2006). The VTA
sends dopaminergic efferents to many brain regions including
the NAc, PfC, and basolateral amygdala. VTA dopamine neurons
express KOR mRNA and the final protein expression patterns
appear to depend on projection target (Ford et al., 2006; Margolis
et al., 2006). Based on retrograde tracing from VTA target sites
and electrophysiological recordings of VTA dopamine neurons
(Margolis et al., 2006), it has been demonstrated that VTA
neurons that project to the NAc express KORs predominantly
on their nerve terminals within the NAc. In contrast, VTA
dopamine neurons that project to the PfC express KORs
predominantly on their cell bodies within the VTA. Consistent
with this, administration of KOR agonists into the NAc decreases
local dopamine concentrations (Donzanti et al., 1992; Spanagel
et al., 1992), most likely by stimulating presynaptic KORs on
dopaminergic afferents from VTA neurons (Svingos et al., 1999).
In a separate study using similar techniques (Ford et al., 2006),
it was shown that KOR activation inhibits VTA dopamine
neurons projecting to the NAc but has little effect on dopamine
neurons projecting to the basolateral amygdala. Furthermore,
KOR activation selectively inhibits somatodendritic dopamine
release (via KORs expressed on dopamine neuron cell bodies) in
NAc projection neurons. DYN can modulate VTA dopaminergic
neurons via actions on non-dopamine neurons as well. For
example, KORs are likely expressed on GABAergic (Ford et al.,
2006; Graziane et al., 2013; Crowley and Kash, 2015) and
glutamatergic (Margolis et al., 2005) neurons that synapse on
dopamine neurons in the VTA. Indeed, DYN has been shown
to inhibit glutamate transmission in the VTA (Mu et al., 2011).
The origin of DYN inputs to the VTA is not fully understood,
but comes in part from the nucleus accumbens and lateral
hypothalamic neurons that co-express orexin (Muschamp et al.,
2014).
KORs and DYN are also enriched in the basolateral amygdala,
the central nucleus of amygdala, and the BNST (Crowley and
Kash, 2015). In the central nucleus of amygdala, pDYN mRNA
is expressed in at least some CRF-expressing neurons (Marchant
et al., 2007). The highest concentration of KOR binding in
the rodent is found in the endopiriform cortex (Le Merrer
et al., 2009). The endopiriform cortex is relatively understudied
but appears to be an area of convergence for sensory and
affect-related information and is involved in aspects of the
storage, consolidation, and retrieval of emotional memories
(de Curtis and Paré, 2004). In the guinea pig endopiriform
cortex, KOR levels are higher in males compared to females
(Wang et al., 2011), but the functional significance of this is
unkown.
In the hippocampus, DYN is localized in dentate gyrus granule
cells, from which it is locally released to act as a retrograde
transmitter inhibiting excitatory inputs within the hippocampus
(Drake et al., 1994). The dentate gyrus granule cells form the
mossy fiber pathway that is involved in learning related to drug
abuse (Torres-Reveron et al., 2009). DYN and ERβ, but not ERα,
are colocalized in the mossy fiber pathway. Female rats in estrus
have been shown to have increased DYN levels in the dentate
gyrus and certain CA3 lamina compared to rats in proestrus or
diestrus (Torres-Reveron et al., 2009). Also, U50,488-stimulated
[35S]GTPγS binding in the dentate gyrus of guinea pigs has been
shown to be higher in females compared to males (Wang et al.,
2011).
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MECHANISMS UNDERLYING SEX
DIFFERENCES IN DYN/KOR FUNCTION
Polymorphisms in the Prodynorphin Gene
Both environmental and genetic factors significantly increase
vulnerability to drug addiction (Tsuang et al., 1996; Clarke et al.,
2012). Most genetic variation in humans is attributable to single
nucleotide polymorphisms (SNPs). These are positions on a DNA
sequence at which two alternative bases occur in at least 1% of the
human population (Wang et al., 1998). The remaining genetic
variation in humans is due to insertions or deletions of one or
more nucleotides in genes, repeat length polymorphisms and
DNA rearrangements (Sachidanandam et al., 2001). Sex-linked
polymorphisms in the pDYN gene have been associated with
increased vulnerability to develop drug addiction (Clarke et al.,
2009). Specifically, two SNPs, rs1997794 in the promoter and
rs1022563 in the 3′ UTR region of the pDYN gene have been
shown to be significantly associated with opioid dependence in
women but not men in a Chinese population, suggesting that
these SNPs confer an increased risk for women (Clarke et al.,
2009). In European Americans, SNPs rs1022563, rs910080, and
rs199774 have been shown to be significantly associated with an
increased risk for opioid addiction in both men and women.
However, the odds ratio was higher in women compared to
men (Clarke et al., 2012). In contrast, no significant associations
with SNPs in the pDYN gene have been found in African
Americans (Clarke et al., 2012). SNPs in the 3′ UTR of the
pDYN gene (rs910080 and rs2235749) have been associated
with decreased pDYN expression (Yuferov et al., 2009). This
raises the possibility that DYN is decreased in women with
pDYN SNPs that are associated with increased risk of developing
opioid dependence. Future studies should determine why the
association of these SNPs with opioid dependence is higher in
women and also whether their presence can predict an increased
risk of developing opioid use disorders in specific subpopulations
of women.
Sex-Linked Modulation of KOR Analgesia
by the Melanocortin-1 Receptor (MC1R) in
Females vs. the NMDA Receptor in Males
One of the most well characterized sex-linked mechanisms in
KOR-mediated opioid analgesia is the selective involvement of
N-methyl-D-aspartate receptors (NMDARs) in males vs. that
of melanocortin-1 receptors (MC1Rs) in females (Mogil and
Bailey, 2010). NMDAR antagonists can block stress- and KOR-
induced analgesia in males but not females (Mogil et al., 1993;
Kavaliers and Galea, 1995; Kavaliers and Choleris, 1997; Mogil
and Belknap, 1997). In contrast, MC1Rs are necessary for KOR-
mediated analgesia in females but not males (Mogil and Bailey,
2010). These differences are hormonally dependent since chronic
estrogen and acute progesterone have been shown to act as a
“switch”: female mice utilize the MC1R system under normal
conditions or after hormone replacement following gonadectomy
but switch to the NMDAR system following gonadectomy or
estropause (a state of reproductive senescence; Sternberg et al.,
2004a,b).
Using Quantitative Trait Locus (QTL) mapping, Mogil
and colleagues demonstrated that a region of distal mouse
chromosome 8 that contains the MC1R gene is linked with
stress-induced analgesia in female, but not male mice. QTL
mapping is a technique in which the coinheritance of continuous
traits and polymorphic DNA markers such as microsatellite
markers or SNPs are used in order to identify the chromosomal
location of genes that are responsible for trait variability (Lander
and Schork, 1994; Mogil et al., 2003). Specifically, Mogil and
colleagues measured U50,488-induced analgesia in mice and
then genotyped them for three microsatellite markers spanning
a 24-cM region on distal chromosome 8. They demonstrated
a significant linkage between genotype and U50,488-induced
analgesia in females, but not males. The QTL accounted for
25% of overall trait variance (Mogil et al., 2003). Female mice
inheriting two copies of an allele at microsatellite marker
D8Mit56 inherited from the DBA/2J background mouse strain,
which is particularly sensitive to the analgesic effects of opioids
(Belknap et al., 1990) displayed twice as much U50,488-induced
analgesia compared to female mice inheriting two copies of an
allele inherited from the C57/6J background mouse strain. The
allelic status of male mice at this marker had no consequence
(Mogil et al., 2003).
In humans, MC1R switches melanin synthesis from the
red/yellow phaeomelanin pathway to the black eumelanin
pathway in both skin and hair (Sturm et al., 2001). Individuals
with red hair are homozygotes or compound heterozygotes
at major MC1R variants (R151C, R160W, D294H), which are
associated with loss of function and reduced cAMP production
(Bastiaens et al., 2001) upon receptor activation with α-
melanocyte stimulating hormone (α-MSH), an endogenous
ligand at MC1Rs. Women with variants of the MC1R gene
that are associated with red hair and fair skin (i.e., loss of
function variants) have been shown to display significantly
greater pentazocine-mediated analgesia than men with the
same variants (Mogil et al., 2003). Although it is not known
how MC1R interacts with KORs in a female-specific manner,
both KORs and MC1Rs signal through cAMP pathways
(Bastiaens et al., 2001) and are found in the periaqueductal
gray (PAG) and locus coeruleus (LC), two brain regions
important for sensory and affective dimensions of pain
(Caruso et al., 2014). One possible mechanism involves
receptor heterodimerization, although this has not been directly
tested.
Heterodimerization of MOR and KOR
Traditionally, GPCRs have been thought to act as monomers,
but more recent research suggests that GPCRs may form
homo or heterodimers as part of their normal trafficking and
function (Prinster et al., 2005). As such, heterodimerization is
an important mechanism underlying receptor function (Kern
et al., 2012). In some cases heterodimerization may even be
required for the surface expression and functionality of a
receptor. Even if heterodimerization is not absolutely required,
it can still result in dramatic changes in receptor pharmacology
(i.e., increase specificity for a ligand), internalization processes
(Prinster et al., 2005; Lohse, 2010), and it can stabilize specific
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receptor conformations that promote coupling with discrete
downstream effectors (Kern et al., 2012).
One of the mechanisms suggested to underlie sex differences
in the antinociceptive effects of opioids is the formation of MOR
and KOR heterodimers (Chakrabarti et al., 2010). MOR/KOR
heterodimers have been shown to be most prevalent in the
spinal cord of proestrous females (cycle stage with highest
estrogen levels), followed by females in diestrous and estrous
and finally in males (Chakrabarti et al., 2010), suggesting that
estrogen contributes to their formation (Figure 2). Consistent
with this, spinal synthesis of estrogen and subsequent rapid
signaling through membrane-localized ERs regulate MOR/KOR
heterodimerization (Liu et al., 2011). Blockade of either ERα, ERβ
or progesterone receptor (PR) substantially reduces MOR/KOR
heterodimers and shifts morphine-induced antinociception
from being KOR-dependent to KOR-independent (Liu et al.,
2011). Exogenous or endogenous estrogen enhances KOR-
mediated antinociception in females, whereas testosterone
has no effect in males (Lawson et al., 2010). Despite the clear
regulation by estrogen, it has also been reported that MOR/KOR
heterodimers are more prevalent in ovariectomized females
compared to males (Chakrabarti et al., 2010) indicating
an additional sex-dependent but estrogen independent
mechanism. MOR/KOR heterodimers have been shown to
utilize spinal DYN1−17 as a substrate for the female-specific KOR
component of spinal morphine antinociception (Chakrabarti
et al., 2010).
To date, MOR and KOR heterodimerization has not been
described in neural circuits that modulate motivated behavior.
The necessary ingredients are present, as there is substantial
overlap in MOR and KOR expression in brain regions such as
the NAc, BNST, PfC, VTA, and amygdala (Le Merrer et al.,
2009). Furthermore, ERα and ERβ are also expressed in these
regions (Figure 2), which would allow for estrogen-mediated
facilitation of MOR/KOR heterodimers, as described above. The
functional consequences of putative MOR/KOR heterodimers
within reward circuits are not easy to conceptualize, as behavioral
effects of MOR and KOR agonists tend to oppose each other.
This is different from pain systems, in which both MOR
and KOR agonists have analgesic properties. A recent study
demonstrated heterodimerization of orexin receptor 1 and KORs
in the VTA (Chen et al., 2015), which is consistent with the
idea that MOR/KOR heterodimers in similar brain regions are
feasible.
Gonadal Hormone Mechanisms of KOR
Function
There is substantial evidence for organizational and activational
roles of gonadal hormones in mediating effects of KORs
(Forman et al., 1989; Limonta et al., 1989; Mogil et al., 1993;
Rasakham and Liu-Chen, 2011), including roles in the processes
described above. However, the actual mechanisms through which
hormones mediate their effects are not fully understood. It is
also important to note that DYN and KOR function can be sex-
dependent but hormone-independent. For example, it has been
shown in the four-core genotype mouse model that XX mice that
have either male or female gonads have higher pDYN mRNA
expression in the striatum compared to XY mice that have either
male or female gonads (Chen et al., 2009). This is likely due to
incomplete inactivation of portions of the X chromosome.
The most straightforward manner in which gonadal steroids
might influence KOR function is via transcriptional mechanisms
involving steroid hormone receptor binding to estrogen or
androgen response elements found in regulatory regions on
genes (Gruber et al., 2004; Klinge et al., 2004; Gottsch et al.,
2009). As an example, estradiol has been shown to decrease
DYN expression in the arcuate nucleus of the hypothalamus
in wild-type but not ERα-/- mice through an ERE-dependent
pathway (Gottsch et al., 2009). These findings suggest that
DYN-expressing neurons in the arcuate play a role in estrogen-
mediated negative feedback of pulsatile gonadotropin-releasing
hormone (GnRH)/luteinizing hormone (LH) release (Mostari
et al., 2013). There is also evidence that testosterone can regulate
DYN expression. In castrated Romney Marsh rams it has been
shown that testosterone treatment increases pDYNmRNA in the
supraoptic nucleus and the BNST during the breeding season
(Scott et al., 2008).
A more indirect mechanism for gonadal hormone control
of gene expression is through modulation of transcription
factor activity. For example, the pDYN gene contains cAMP
response element (CRE) sequences in its promoter that bind
the transcription factor CREB (Douglass et al., 1994; Cole et al.,
1995). Estrogen treatment has been shown to increase CREB
phosphorylation in the anteroventral periventricular nucleus,
resulting in elevated pCREB in approximately 25% of pDYN-
positive neurons in this region (Gu et al., 1996).
Gonadal hormones can also influence DYN and KOR
function through rapid effects at membrane receptors and non-
transcriptional effects on second messenger pathways. Pain
tolerance is increased during pregnancy (Cogan and Spinnato,
1986), an effect due in part to enhanced KOR-mediated
antinociception in the spinal cord (Gupta et al., 2001; Gintzler
et al., 2008). This phenomenon of gestational antinociception
can be mimicked in gonadectomized rodents by administering
pregnancy level concentrations of estrogen and progesterone
(Dawson-Basoa and Gintzler, 1998; Gintzler and Liu, 2012).
It has been shown that ERα is coexpressed with DYN in the
dorsal horn of the spinal cord, and this coexpression is increased
during pregnancy or after estrogen and progesterone treatment
(Gintzler et al., 2008). ERα activation contributes to increased
DYN release in the spinal cord, possibly through ERα-mediated
activation of PKA and MAPK pathways (Gintzler et al., 2008).
An alternate, but not mutually exclusive, possibility is that
membrane bound ERs increase neuronal excitability through
activation of metabotropic glutamate receptors (Boulware et al.,
2005). In addition to coexpression of ERα and DYN, delta
opioid receptors (DORs) are expressed on DYN terminals in
the dorsal horn. Under normal (non-pregnant) conditions,
DOR activation inhibits DYN release in the spinal cord and
attenuates KOR-mediated analgesia. However, during pregnancy,
this effect is switched such that DOR activation stimulates DYN
release and facilitates gestational antinociception. Although the
mechanisms underlying this switch in DOR function are not
understood, it is likely mediated by effects of ER activation on
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FIGURE 2 | Sex-linked heterodimerization of mu and kappa opioid receptors.MORs and KORs are expressed in the spinal cord in both males and females. In
males, morphine-mediated analgesia does not require concomitant activation of these receptors, whereas activation of MOR/KOR heterodimers in females is necessary
for morphine analgesia. (A). MOR/KOR heterodimers are more highly expressed in ovariectomized females compare to males (B). Estrous cycle stage and estrogen levels
affect the formation of heterodimers in the female spinal cord. Levels of MOR/KOR heterodimers are higher during proestrus (C) compared to diestrus (D), suggesting an
estrogen-dependent mechanism underlies their formation (Chakrabarti et al., 2010; Liu et al., 2011). KOR, kappa opioid receptor; MOR, mu opioid receptor.
intracellular signaling events that alter DOR G-protein coupling
from inhibitory to excitatory (Gintzler et al., 2008).
APPLYING MECHANISMS OF SEX
DIFFERENCES IN KOR/DYN SYSTEMS
FROM PAIN AND OTHER SYSTEMS TO
DRUG ADDICTION
There are at least two ways in which mechanistic studies of sex
differences in KOR/DYN systems within pain circuits can apply
to drug addiction. First, many of the brain regions subserving
pain are also important for reward and affective states (see
Figure 1), raising the possibility that sex differences in pain
modulation—particularly the affective component of pain—also
hold true for sex differences in addiction. As one example,
MC1Rs and KORs are colocalized in the periaqueductal gray
(PAG) and locus coeruleus (LC), two brain regions important
for sensory and affective dimensions of pain (Caruso et al.,
2014) as well as somatic and affective dimensions of opiate
withdrawal (Williams et al., 2001). There is evidence that
KOR activation is necessary for morphine withdrawal-induced
conditioned place aversions (Kelsey et al., 2015). Although not
yet studied, it is possible that KOR-mediated aversive effects of
morphine withdrawal in females depends onMC1Rs. The second
way in which mechanisms underlying sex differences in KOR
function can apply to addiction is that molecular and biochemical
processes are typically similar across brain regions. What makes
the functional difference is the neural circuit within which the
processes are found. As one example, sex-linked polymorphisms
in the pDYN gene will result in alterations in DYN in all cells.
The effect these alterations have will depend on the particular cell
type and brain region studied.
FUTURE DIRECTIONS
Major technical advances in genetics, molecular biology, and
neurophysiology have enabled the discovery of genes, cellular
mechanisms and neural circuits necessary for the transition from
drug use to drug addiction. Most of these advances have been
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made selectively in male animal models, but fortunately more
and more research is being conducted on males and females
in parallel. In our view, it is essential to keep in mind that
sex differences occur at multiple levels (McCarthy and Arnold,
2011). Of particular importance to this review, sex differences can
manifest as behavioral differences in which the average behavior
is different in males and females. This type of sex difference
is the most commonly reported and includes the discussed
differences in pain thresholds, analgesic efficacy of KOR ligands,
and aversive effects of KOR activation, to name a few. These
behavioral differences suggest that there are distinct underlying
molecular mechanisms betweenmales and females. Another level
at which sex differences can occur is when behavioral endpoints
are the same in males and females, but underlying neural
mechanisms differ. This type of sex difference is often missed
since there is no overt sex difference in behavior. An example
of this is the female requirement for MC1R activation but male
requirement for NMDA receptor activation in KOR-mediated
analgesia.
A primary goal of this review was to synthesize what is known
about sex differences in DYN and KOR systems and relate this to
drug addiction. At this point, very little is known that directly
connects sex differences in DYN and KOR function with sex
differences in drug addiction. We identify three major gaps in
knowledge:
(1) Are there sex differences in how DYN and KORs contribute
to different facets of addictive behavior (e.g., acquisition,
maintenance, dependence, withdrawal, craving, and relapse)?
(2) Are there sex differences in DYN and KOR expression
levels and patterns, DYN release, and KOR coupling to
downstream effectors within neural circuits that modulate
addictive behavior (e.g., mesocorticolimbic system, extended
amygdala, hypothalamic pituitary adrenal [HPA] axis)?
(3) Is the function of DYN and KORs within these addiction-
related neural circuits dependent on gonadal hormones? If so,
what are the mechanisms?
Based on genetic association studies of the pDYN gene in
drug-dependent populations (Clarke et al., 2009; Yuferov et al.,
2009) and the known mechanisms underlying KOR function
in antinociception described in the preceding section, we
propose and encourage similar studies in animal models of
drug addiction. For example, is there evidence for KOR/MOR
heterodimers in limbic brain circuits? Are either MC1R or
NMDA receptors necessary for KOR-mediated effects on
motivated behavior? Can steroid hormone receptors modulate
transcription of DYN or KOR or modify KOR-mediated
intracellular signaling pathways in limbic circuits? Given the
impact of negative affect on the maintenance of addiction,
delineating the underlying mechanisms in both males and
females will allow the development of treatments that are
maximally effective in each sex.
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